Sodium valproate: balancing benefits and risks especially in people of childbearing potential.

Authors

Dan McLaughlin

Published in

Australian prescriber. Volume 49. Issue 3. Pages 84-87.

Abstract

Sodium valproate (valproate) is an approved treatment for epilepsy and bipolar disorder in Australia. It is associated with a range of adverse effects that require monitoring and may limit its use. Due to its teratogenicity, valproate should not be prescribed to women of childbearing potential. Lamotrigine or levetiracetam are preferred alternatives in epilepsy. If no alternative is suitable and valproate is prescribed, contraception should be co-prescribed. Concerns have been raised about the potential risk of neurodevelopmental disorders in children born to men taking valproate; although these findings have not been confirmed in robust studies, male patients should be informed of the potential risk.

PMID:
42312305
Bibliographic data and abstract were imported from PubMed on 18 Jun 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.